Preclinical models have demonstrated that PTEN loss is a critical driver of αPD-1 resistance in NSCLC, primarily through increased infiltration of Tregs in the TME—a phenomenon also observed in patients (94). The gene discussed is PTEN; the disease is non-small cell lung carcinoma.